Dashboard
Manage Tickers

ARVN ARVINAS, INC.

Nasdaq arvinas.com


$ 11.21 $ 0.02 (0.18 %)    

Tuesday, 11-Nov-2025 15:59:56 EST
CLICK TO SEE RELEVANT LITIGATION UPDATES
Y-mAbs Therapeutics, Inc. | YMAB | Take Action!
QQQ $ 622.49 $ 0.90 (0.15 %)
DIA $ 479.63 $ 5.34 (1.13 %)
SPY $ 683.37 $ 2.90 (0.43 %)
TLT $ 89.91 $ 0.01 (0.01 %)
GLD $ 380.58 $ -0.09 (-0.02 %)
$ 11.21
$ 11.19
$ 10.25 x 59
$ 11.55 x 1
$ 11.09 - $ 11.51
$ 5.90 - $ 27.76
2,169,369
na
719.95M
$ 1.43
nm
TBD
na
na ($ 0.00)
na
TBD na
How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In
# Filing Date Period End Date Type Report Link
1 11-05-2025 09-30-2025 10-Q
2 08-06-2025 06-30-2025 10-Q
3 05-01-2025 03-31-2025 10-Q
4 02-11-2025 12-31-2024 10-K
5 10-30-2024 09-30-2024 10-Q
6 07-30-2024 06-30-2024 10-Q
7 05-07-2024 03-31-2024 10-Q
8 02-27-2024 12-31-2023 10-K
9 11-07-2023 09-30-2023 10-Q
10 08-08-2023 06-30-2023 10-Q
11 05-05-2023 03-31-2023 10-Q
12 02-23-2023 12-31-2022 10-K
13 11-09-2022 09-30-2022 10-Q
14 08-04-2022 06-30-2022 10-Q
15 05-05-2022 03-31-2022 10-Q
16 02-28-2022 12-31-2021 10-K
17 11-03-2021 09-30-2021 10-Q
18 08-05-2021 06-30-2021 10-Q
19 05-04-2021 03-31-2021 10-Q
20 03-01-2021 12-31-2020 10-K
21 11-05-2020 09-30-2020 10-Q
22 08-04-2020 06-30-2020 10-Q
23 04-28-2020 03-31-2020 10-Q
24 03-16-2020 12-31-2019 10-K
25 11-04-2019 09-30-2019 10-Q
26 08-05-2019 06-30-2019 10-Q
27 05-09-2019 03-31-2019 10-Q
28 03-26-2019 12-31-2018 10-K
29 11-14-2018 09-30-2018 10-Q
Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In
# Date Analyst Firm Upside/Downside Price Target Change Rating Change Current Rating

News

OPINIONS

stephens--co-maintains-overweight-on-arvinas-raises-price-target-to-15
Stephens & Co. Maintains Overweight on Arv...
11/10/2025 14:13:28

Stephens & Co. analyst Sudan Loganathan maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target fr...

wells-fargo-maintains-overweight-on-arvinas-lowers-price-target-to-15
Wells Fargo Maintains Overweight on Arvina...
11/06/2025 15:41:58

Wells Fargo analyst Derek Archila maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target from $16 to ...

barclays-maintains-overweight-on-arvinas-raises-price-target-to-16
Barclays Maintains Overweight on Arvinas, ...
11/06/2025 14:27:18

Barclays analyst Etzer Darout maintains Arvinas (NASDAQ:ARVN) with a Overweight and raises the price target from $15 to $16.

arvinas-q3-eps-048-beats-081-estimate-sales-41900m-beat-23600m-estimate
Arvinas Q3 EPS $(0.48) Beats $(0.81) Estim...
11/05/2025 12:06:07

Arvinas (NASDAQ:ARVN) reported quarterly losses of $(0.48) per share which beat the analyst consensus estimate of $(0.81) by 40...

earnings-scheduled-for-november-5-2025
Earnings Scheduled For November 5, 2025
11/05/2025 11:12:12

arvinas-to-present-preclinical-data-for-its-protac-bcl6-degrader-arv-393-in-combination-with-glofitamab-at-2025-american-society-of-hematology-annual-meeting
Arvinas To Present Preclinical Data For It...
11/03/2025 21:02:36

NEW HAVEN, Conn., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Arvinas, Inc. (NASDAQ:ARVN), a clinical-stage biotechnology company creatin...

btig-maintains-buy-on-arvinas-raises-price-target-to-14
BTIG Maintains Buy on Arvinas, Raises Pric...
10/30/2025 11:36:25

BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and raises the price target from $10 to $14.

arvinas-announces-preclinical-data-for-arv-806-showing-robust-differentiated-activity-in-models-of-kras-g12d-mutated-cancer-at-2025-aacr-nci-eortc-international-conference
Arvinas Announces Preclinical Data For ARV...
10/24/2025 20:02:42

– In vivo, ARV-806 demonstrated robust and durable KRAS G12D degradation, leading to significant tumor growth inhibition in mod...

arvinas-to-present-preclinical-data-for-arv-806-at-2025-at-aacr-nci-eortc-international-conference-in-boston
Arvinas To Present Preclinical Data For AR...
10/22/2025 20:03:04

arvinas-reports-vepdegestrant-maintained-quality-of-life-and-delayed-symptom-worsening-in-esr1-mutated-erher2--advanced-breast-cancer-patients
Arvinas Reports Vepdegestrant Maintained Q...
10/20/2025 08:36:04

– Data demonstrated that vepdegestrant maintained patients' quality of life for statistically significantly longer and dela...

forecasting-the-future-7-analyst-projections-for-arvinas
Forecasting The Future: 7 Analyst Projecti...
10/15/2025 22:01:44

this-ge-vernova-analyst-turns-bearish-here-are-top-5-downgrades-for-wednesday
This GE Vernova Analyst Turns Bearish; Her...
10/15/2025 13:49:56

karooooo-posts-downbeat-earnings-joins-asp-isotopes-and-other-big-stocks-moving-lower-in-wednesdays-pre-market-session
Karooooo Posts Downbeat Earnings, Joins AS...
10/15/2025 12:01:14

goldman-sachs-downgrades-arvinas-to-sell-lowers-price-target-to-6
Goldman Sachs Downgrades Arvinas to Sell, ...
10/15/2025 11:24:51

Goldman Sachs analyst Paul Choi downgrades Arvinas (NASDAQ:ARVN) from Neutral to Sell and lowers the price target from $8 to...

Core News & Articles
Arvinas And Pfizer To Highlight New Vepdeg...
10/13/2025 11:08:29

Presentation to include new patient-reported outcomes (PRO) data from the Phase 3 VERITAC-2 clinical trial 

reported-sunday-arvinas-unveils-late-breaking-phase-1-data-for-arv-102-showing-90-lrrk2-reduction-and-modulation-of-neuroinflammatory-pathways
Reported Sunday, Arvinas Unveils Late-Brea...
10/06/2025 06:29:32

arvinas-to-present-arv-102-data-at-2025-international-congress-of-parkinsons-disease-and-movement-disorders-oct-7-and-8
Arvinas To Present ARV-102 Data At 2025 In...
10/01/2025 11:03:59

btig-maintains-buy-on-arvinas-lowers-price-target-to-10
BTIG Maintains Buy on Arvinas, Lowers Pric...
09/18/2025 14:08:11

BTIG analyst Jeet Mukherjee maintains Arvinas (NASDAQ:ARVN) with a Buy and lowers the price target from $16 to $10.

stephens--co-maintains-overweight-on-arvinas-lowers-price-target-to-14
Stephens & Co. Maintains Overweight on Arv...
09/18/2025 12:03:47

Stephens & Co. analyst Sudan Loganathan maintains Arvinas (NASDAQ:ARVN) with a Overweight and lowers the price target fr...

arvinas-to-reduce-workforce-by-15-most-significant-reductions-being-roles-related-to-vepdegestrant-commercialization-expects-45m-costs-for-workforce-reduction
Arvinas To Reduce Workforce By 15%; Most S...
09/17/2025 20:53:03

CORE & Plaid

CORE & Plaid

CORE Finalist

CLASS ACTION DEADLINES - JOIN NOW!

NEW CASE INVESTIGATION